These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. Ahmed MH; Osman KA Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887 [No Abstract] [Full Text] [Related]
10. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142 [TBL] [Abstract][Full Text] [Related]
16. [News from the Cochrane Library: treatment of nonalcoholic fatty liver disease and steatohepatitis]. Timmer A Z Gastroenterol; 2007 Feb; 45(2):191-3. PubMed ID: 17304406 [No Abstract] [Full Text] [Related]
19. 4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome. Jetté L; Harvey L; Eugeni K; Levens N Curr Opin Investig Drugs; 2009 Apr; 10(4):353-8. PubMed ID: 19337956 [TBL] [Abstract][Full Text] [Related]
20. [Place of hypoglycemic sulfonamides in treatment of steatosis of nutritional origin]. Dorf G; Tutin M; Bour H; Guy-Grand B Therapeutique; 1969 May; 45(5):536-7. PubMed ID: 5791835 [No Abstract] [Full Text] [Related] [Next] [New Search]